Last reviewed · How we verify

Celtect — Competitive Intelligence Brief

Celtect (OXATOMIDE) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: oxatomide. Area: Hematology.

marketed oxatomide P2X purinoceptor 7, 5-hydroxytryptamine receptor 2A, 5-hydroxytryptamine receptor 2B Hematology Small molecule Live · refreshed every 30 min

Target snapshot

Celtect (OXATOMIDE).

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Celtect TARGET OXATOMIDE marketed oxatomide P2X purinoceptor 7, 5-hydroxytryptamine receptor 2A, 5-hydroxytryptamine receptor 2B

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (oxatomide class)

  1. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Celtect — Competitive Intelligence Brief. https://druglandscape.com/ci/oxatomide. Accessed 2026-05-14.

Build your own brief

Pick any drug + add comparators: